The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Open accessAbstract
Purpose: We report the first-in-human phase Ia study to our knowledge ( ClinicalTrials.gov identifier: NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)–selective inhibitor. Patients and Methods: In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule. In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor–positive/human epidermal growth factor receptor 2–negative breast cancer received alpelisib 400 mg once daily. Results: One hundred thirty-four patients received treatment. Alpelisib maximum tolerated doses were established as 400 mg once daily and 150 mg twice daily. Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1). Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%). Alpelisib was rapidly absorbed; half-life was 7.6 hours at 400 mg once daily with minimal accumulation. Objective tumor responses were observed at doses ≥ 270 mg once daily; overall response rate was 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses). Stable disease was achieved in 70 (52.2%) patients and was maintained > 24 weeks in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%. In patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative breast cancer, median progression-free survival was 5.5 months. Frequently mutated genes (≥ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%). Conclusion: Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Integrated genomic and molecular characterization of cervical cancer
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature21386 · Cited by 1,479
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Self-citationEngelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Sequence analysis of mutations and translocations across breast cancer subtypes
Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K. K., Carter, S. L., Frederick, A. M., Lawrence, M. S., Sivachenko, A. Y., Sougnez, C., Zou, L., et al. (2012) · Nature · doi:10.1038/nature11154 · Cited by 1,179
Self-citationFrequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 589
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationBaselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Self-citationFritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Self-citationPicking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Self-citationCritical aspects of the Bayesian approach to phase I cancer trials
Neuenschwander, B., Branson, M., & Gsponer, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3230 · Cited by 439
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432
Self-citationFrequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Van Keymeulen, A., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 354
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343
Self-citationElkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
Self-citationPIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
Self-citationPIK3CAH1047R induces multipotency and multi-lineage mammary tumours
Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., et al. (2015) · Nature · doi:10.1038/nature14669 · Cited by 327
Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D., Berger, M. F., Won, H. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 319
Self-citationSarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Toska, E., Osmanbeyoglu, H. U., Castel, P., Chan, C., Hendrickson, R. C., Elkabets, M., Dickler, M. N., Scaltriti, M., Leslie, C. S., Armstrong, S. A., et al. (2017) · Science · doi:10.1126/science.aah6893 · Cited by 265
Self-citationAssessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Janku, F., Hong, D. S., Fu, S., Piha-Paul, S. A., Naing, A., Falchook, G. S., Tsimberidou, A. M., Stepanek, V. M., Moulder, S. L., Lee, J. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.035 · Cited by 237
Self-citationBusaidy, N. L., Farooki, A., Dowlati, A., Perentesis, J. P., Dancey, J. E., Doyle, L. A., Brell, J. M., & Siu, L. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7356 · Cited by 231
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke-Hale, K., Sahin, A., Liu, S., Barrera, J. A., Burgues, O., Lluch, A. M., Chen, H., Hortobagyi, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1089 · Cited by 219
Kinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59309 · Cited by 214
Costa, C., Ebi, H., Martini, M., Beausoleil, S. A., Faber, A. C., Jakubik, C. T., Huang, A., Wang, Y., Nishtala, M., Hall, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.007 · Cited by 203
Self-citationRodon, J., Braña, I., Siu, L. L., De Jonge, M. J., Homji, N., Mills, D., Di Tomaso, E., Sarr, C., Trandafir, L., Massacesi, C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0082-9 · Cited by 186
Self-citationShapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Self-citationJankú, F., Juric, D., Cortés, J., Rugo, H. S., Burris, H. A., Schüler, M., Deschler-Baier, B., Middleton, M. R., Gil-Martín, M., Berlin, J. D., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-pd5-5 · Cited by 17
Self-citation
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citationPI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Metadata
- Authors
- Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., Rugo, H. S., Seggewiss-Bernhardt, R., Huang, A., Bootle, D., Demanse, D., Blumenstein, L., Coughlin, C., Quadt, C., & Baselga, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-05-01
- Volume
- 36
- Issue
- 13
- Pages
- 1291-1299
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2786945112
- Cited by
- 431
- References
- 35
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.